159 related articles for article (PubMed ID: 37604475)
1. Severe Hemolysis during Primaquine Radical Cure of Plasmodium vivax Malaria: Two Systematic Reviews and Individual Patient Data Descriptive Analyses.
Yilma D; Groves ES; Brito-Sousa JD; Monteiro WM; Chu C; Thriemer K; Commons RJ; Lacerda MVG; Price RN; Douglas NM
Am J Trop Med Hyg; 2023 Oct; 109(4):761-769. PubMed ID: 37604475
[TBL] [Abstract][Full Text] [Related]
2. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Rodrigo C; Rajapakse S; Fernando D
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD010458. PubMed ID: 32892362
[TBL] [Abstract][Full Text] [Related]
3. The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia.
Thriemer K; Poespoprodjo JR; Kenangalem E; Douglas NM; Sugiarto P; Anstey NM; Simpson JA; Price RN
PLoS Negl Trop Dis; 2020 Nov; 14(11):e0008838. PubMed ID: 33175835
[TBL] [Abstract][Full Text] [Related]
4. Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax.
Milligan R; Daher A; Villanueva G; Bergman H; Graves PM
Cochrane Database Syst Rev; 2020 Aug; 8():CD012656. PubMed ID: 32816320
[TBL] [Abstract][Full Text] [Related]
5. Risk of hemolysis in Plasmodium vivax malaria patients receiving standard primaquine treatment in a population with high prevalence of G6PD deficiency.
Liu H; Zeng W; Malla P; Wang C; Lakshmi S; Kim K; Menezes L; Yang Z; Cui L
Infection; 2023 Feb; 51(1):213-222. PubMed ID: 35976559
[TBL] [Abstract][Full Text] [Related]
6. Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency.
Taylor WRJ; Kheng S; Muth S; Tor P; Kim S; Bjorge S; Topps N; Kosal K; Sothea K; Souy P; Char CM; Vanna C; Ly P; Khieu V; Christophel E; Kerleguer A; Pantaleo A; Mukaka M; Menard D; Baird JK
J Infect Dis; 2019 Oct; 220(11):1750-1760. PubMed ID: 31549159
[TBL] [Abstract][Full Text] [Related]
7. Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study.
Devine A; Battle KE; Meagher N; Howes RE; Dini S; Gething PW; Simpson JA; Price RN; Lubell Y
PLoS Med; 2021 Jun; 18(6):e1003614. PubMed ID: 34061843
[TBL] [Abstract][Full Text] [Related]
8. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis.
Rajasekhar M; Simpson JA; Ley B; Edler P; Chu CS; Abreha T; Awab GR; Baird JK; Bancone G; Barber BE; Grigg MJ; Hwang J; Karunajeewa H; Lacerda MVG; Ladeia-Andrade S; Llanos-Cuentas A; Pukrittayakamee S; Rijal KR; Saravu K; Sutanto I; Taylor WRJ; Thriemer K; Watson JA; Guerin PJ; White NJ; Price RN; Commons RJ;
Lancet Infect Dis; 2024 Feb; 24(2):184-195. PubMed ID: 37748497
[TBL] [Abstract][Full Text] [Related]
9. [Clinical and laboratorial alterations in Plasmodium vivax malaria patients and glucose-6-phosphate dehydrogenase deficiency treated with primaquine at 0.50 mg/kg/day].
Silva MC; Santos EB; Costal EG; Filho MG; Guerreiro JF; Póvoa MM
Rev Soc Bras Med Trop; 2004; 37(3):215-7. PubMed ID: 15330059
[TBL] [Abstract][Full Text] [Related]
10. The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.
Commons RJ; Simpson JA; Thriemer K; Chu CS; Douglas NM; Abreha T; Alemu SG; Añez A; Anstey NM; Aseffa A; Assefa A; Awab GR; Baird JK; Barber BE; Borghini-Fuhrer I; D'Alessandro U; Dahal P; Daher A; de Vries PJ; Erhart A; Gomes MSM; Grigg MJ; Hwang J; Kager PA; Ketema T; Khan WA; Lacerda MVG; Leslie T; Ley B; Lidia K; Monteiro WM; Pereira DB; Phan GT; Phyo AP; Rowland M; Saravu K; Sibley CH; Siqueira AM; Stepniewska K; Taylor WRJ; Thwaites G; Tran BQ; Hien TT; Vieira JLF; Wangchuk S; Watson J; William T; Woodrow CJ; Nosten F; Guerin PJ; White NJ; Price RN
BMC Med; 2019 Aug; 17(1):151. PubMed ID: 31366382
[TBL] [Abstract][Full Text] [Related]
11. G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients.
Avalos S; Mejia RE; Banegas E; Salinas C; Gutierrez L; Fajardo M; Galo S; Pinto A; Mejia A; Fontecha G
Malar J; 2018 Nov; 17(1):415. PubMed ID: 30409136
[TBL] [Abstract][Full Text] [Related]
12. Primaquine treatment and relapse in Plasmodium vivax malaria.
Rishikesh K; Saravu K
Pathog Glob Health; 2016; 110(1):1-8. PubMed ID: 27077309
[TBL] [Abstract][Full Text] [Related]
13. Single-Nucleotide Polymorphisms in Glucose-6-Phosphate Dehydrogenase and their Relevance for the Deployment of Primaquine as a Radical Cure for Malaria.
Nain M; Gill J; Mohan M; Sharma A
Am J Trop Med Hyg; 2023 Mar; 108(3):470-476. PubMed ID: 36746659
[TBL] [Abstract][Full Text] [Related]
14. Effects of Host Genetic Polymorphisms on the Efficacy of the Radical Cure Malaria Drug Primaquine.
Nain M; Mohan M; Sharma A
Am J Trop Med Hyg; 2022 Jan; 106(3):764-767. PubMed ID: 35008050
[TBL] [Abstract][Full Text] [Related]
15. Real-life implementation of a G6PD deficiency screening qualitative test into routine vivax malaria diagnostic units in the Brazilian Amazon (SAFEPRIM study).
Brito-Sousa JD; Murta F; Vitor-Silva S; Sampaio VS; Mendes MO; Brito MAM; Batista TSB; Santos APC; Marques LLG; Barbosa LRA; Melo MM; Baia-da-Silva DC; Silva-Neto AV; Santos TC; Souza BKA; Figueiredo EFG; Silva EL; Rodovalho S; Nakagawa TH; Arcanjo AR; Siqueira AM; Melo GC; Recht J; Domingo GJ; Bassat Q; Bancone G; Monteiro WM; Lacerda MVG
PLoS Negl Trop Dis; 2021 May; 15(5):e0009415. PubMed ID: 34003840
[TBL] [Abstract][Full Text] [Related]
16. Safety of primaquine in infants with Plasmodium vivax malaria in Papua, Indonesia.
Setyadi A; Arguni E; Kenangalem E; Hasanuddin A; Lampah DA; Thriemer K; Anstey NM; Sugiarto P; Simpson JA; Price RN; Douglas NM; Poespoprodjo JR
Malar J; 2019 Apr; 18(1):111. PubMed ID: 30940140
[TBL] [Abstract][Full Text] [Related]
17. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Llanos-Cuentas A; Lacerda MVG; Hien TT; Vélez ID; Namaik-Larp C; Chu CS; Villegas MF; Val F; Monteiro WM; Brito MAM; Costa MRF; Chuquiyauri R; Casapía M; Nguyen CH; Aruachan S; Papwijitsil R; Nosten FH; Bancone G; Angus B; Duparc S; Craig G; Rousell VM; Jones SW; Hardaker E; Clover DD; Kendall L; Mohamed K; Koh GCKW; Wilches VM; Breton JJ; Green JA
N Engl J Med; 2019 Jan; 380(3):229-241. PubMed ID: 30650326
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of antimalarial activity and toxicity of a new primaquine prodrug.
Davanço MG; Aguiar AC; Dos Santos LA; Padilha EC; Campos ML; de Andrade CR; da Fonseca LM; Dos Santos JL; Chin CM; Krettli AU; Peccinini RG
PLoS One; 2014; 9(8):e105217. PubMed ID: 25133630
[TBL] [Abstract][Full Text] [Related]
19. Primaquine-induced Severe Hemolysis in the Absence of Concomitant Malaria: Effects on G6PD Activity and Renal Function.
Douglas NM; Piera KA; Rumaseb A; Ley B; Anstey NM; Price RN
Am J Trop Med Hyg; 2023 Jan; 108(1):76-80. PubMed ID: 36509054
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia.
Nelwan EJ; Ekawati LL; Tjahjono B; Setiabudy R; Sutanto I; Chand K; Ekasari T; Djoko D; Basri H; Taylor WR; Duparc S; Subekti D; Elyazar I; Noviyanti R; Sudoyo H; Baird JK
BMC Med; 2015 Dec; 13():294. PubMed ID: 26654101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
